Evidence map›Paper›PMID 36612628›Full record

ArticleInternational journal of environmental research and public health2022

Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer.

Chun-Yu Hsieh, Chia-Yen Lin, Shian-Shiang Wang, Ying-Erh Chou, Ming-Hsien Chien, Yu-Ching Wen, Ming-Ju Hsieh, Shun-Fa Yang

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Chun-Yu HsiehInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Chia-Yen LinInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.ORCID 0000-0002-6303-2187
Shian-Shiang WangDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 407, Taiwan.ORCID 0000-0003-3032-0198
Ying-Erh ChouSchool of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Ming-Hsien ChienGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-0084-7231
Yu-Ching WenDepartment of Urology, Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan.
Ming-Ju HsiehOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.ORCID 0000-0001-9726-3234
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.ORCID 0000-0002-0365-7927
Chung Shan Medical University · TWWan Fang Hospital · TWChung Shan Medical University Hospital · TWNational Chi Nan University · TWNational Chung Hsing University · TWTaichung Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tissue inhibitors of metalloproteinases-3 (TIMP3) are not only endogenous regulators of matrix metalloproteinases (MMPs), but also induce apoptosis and inhibit endothelial cell migration and angiogenesis. The focus of this study was to investigate the relationship between TIMP3 genetic polymorphisms and biochemical recurrence and clinicopathological features of prostate cancer. The TIMP3 rs9619311, rs9862, and rs11547635 genetic polymorphisms were analyzed by real-time polymerase chain reaction to determine their genotypic distributions in 579 patients with prostate cancer. This study found that individuals with the TIMP3 rs9619311 TC or TC + CC genotypes have a significantly higher risk of biochemical recurrence of prostate cancer (

Indexed as

Prostatic NeoplasmsTissue Inhibitor of Metalloproteinase-3GenotypeHumansMaleMetalloproteasesPolymorphism, GeneticProstate-Specific AntigenMetalloproteasesProstate-Specific AntigenTissue Inhibitor of Metalloproteinase-3biochemical recurrencepolymorphismprostate cancerTIMP3

Identifiers

PMID36612628
PMCPMC9819570
OpenAlexW4312201963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.